HTT and Huntington disease: In HD, a non-selective ASO termed RG6042 (previously IONIS-HTTRX) demonstrated efficacy in three different HD mouse models (YAC128, R6/2, BACHD) with approximately 80% reduction of mHTT mRNA and 63% reduction of mutant huntingtin protein.